Heartflow Reports First Quarter 2026 Financial Results and Raises Full Year 2026 Guidance

Heartflow, Inc. (Nasdaq: HTFL), a leader in AI technology for coronary artery disease (CAD), reported first-quarter 2026 financial results on May 14, 2026. Total revenue reached $52.6 million, marking a 41% year-over-year increase, with U.S. revenue at $48.3 million (up 42%) and international revenue at $4.3 million (up 34%). The growth was primarily driven by increased FFRCT volume, an AI-powered diagnostic tool for CAD. Gross profit rose to $42.2 million from $27.9 million in the prior year, with gross margins expanding to 80.2% (80.5% non-GAAP) from 75.1% (75.3% non-GAAP). The company cited AI efficiency initiatives and higher case volume as key factors, though operating expenses increased to $71.7 million due to investments in sales, technology, and clinical research. A $7.5 million non-cash impairment charge was recorded for relocating its headquarters from Mountain View to San Francisco. For the full year 2026, Heartflow raised revenue guidance to $228–232 million (29–32% growth) from its prior forecast of $218–222 million (24–26% growth). Non-GAAP gross margins are now expected to reach approximately 81%. Despite a net operating loss of $29.5 million, cash reserves totaled $254.9 million as of March 31, 2026. The company will host a conference call on May 14, 2026, at 1:30 p.m. PT to discuss results further. Heartflow’s financial performance reflects its focus on scaling AI-driven diagnostics while managing operational costs amid expansion efforts.